Walgreens Boots Alliance (NASDAQ:WBA) Given New $10.00 Price Target at Evercore ISI

Walgreens Boots Alliance (NASDAQ:WBA) had its price target decreased by Evercore ISI from $17.00 to $10.00 in a research report released on Friday, Benzinga reports. Evercore ISI currently has an in-line rating on the pharmacy operator’s stock.

WBA has been the topic of a number of other research reports. Bank of America lowered their price target on Walgreens Boots Alliance from $23.00 to $22.00 and set an underperform rating on the stock in a report on Tuesday, March 26th. Raymond James restated a market perform rating on shares of Walgreens Boots Alliance in a research report on Tuesday, March 26th. TD Cowen decreased their price objective on shares of Walgreens Boots Alliance from $37.00 to $35.00 and set a buy rating on the stock in a research report on Wednesday, April 3rd. Truist Financial restated a hold rating and set a $25.00 target price on shares of Walgreens Boots Alliance in a report on Monday, April 1st. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on shares of Walgreens Boots Alliance from $23.00 to $22.00 and set a hold rating on the stock in a report on Wednesday, April 3rd. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of Hold and a consensus price target of $20.64.

Walgreens Boots Alliance Stock Down 0.8 %

Shares of WBA opened at $12.10 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.32 and a current ratio of 0.65. The company’s 50 day simple moving average is $16.49 and its 200-day simple moving average is $20.19. Walgreens Boots Alliance has a 12-month low of $11.68 and a 12-month high of $31.32.

Walgreens Boots Alliance (NASDAQ:WBA) last posted its quarterly earnings data on Thursday, June 27th. The pharmacy operator reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $0.67 by ($0.04). Walgreens Boots Alliance had a negative net margin of 3.99% and a positive return on equity of 12.63%. The firm had revenue of $36.40 billion during the quarter, compared to analysts’ expectations of $35.94 billion. During the same quarter last year, the business earned $1.00 earnings per share. The business’s quarterly revenue was up 2.8% on a year-over-year basis. Sell-side analysts expect that Walgreens Boots Alliance will post 2.88 earnings per share for the current year.

Walgreens Boots Alliance Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 12th. Stockholders of record on Tuesday, May 21st were paid a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 8.27%. The ex-dividend date of this dividend was Monday, May 20th. Walgreens Boots Alliance’s dividend payout ratio is currently -14.84%.

Insider Transactions at Walgreens Boots Alliance

In related news, CFO Manmohan Mahajan purchased 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was purchased at an average price of $19.38 per share, with a total value of $116,280.00. Following the completion of the transaction, the chief financial officer now owns 166,969 shares of the company’s stock, valued at approximately $3,235,859.22. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Manmohan Mahajan bought 6,000 shares of Walgreens Boots Alliance stock in a transaction that occurred on Tuesday, April 2nd. The shares were purchased at an average price of $19.38 per share, for a total transaction of $116,280.00. Following the completion of the acquisition, the chief financial officer now owns 166,969 shares of the company’s stock, valued at $3,235,859.22. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Inderpal S. Bhandari purchased 3,000 shares of the company’s stock in a transaction on Thursday, April 11th. The shares were purchased at an average price of $18.05 per share, with a total value of $54,150.00. Following the completion of the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at $54,150. The disclosure for this purchase can be found here. Insiders own 17.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Quadrant Capital Group LLC raised its stake in shares of Walgreens Boots Alliance by 33.8% in the 4th quarter. Quadrant Capital Group LLC now owns 7,494 shares of the pharmacy operator’s stock valued at $196,000 after acquiring an additional 1,893 shares during the period. Syon Capital LLC purchased a new position in Walgreens Boots Alliance in the fourth quarter valued at about $333,000. New York Life Investment Management LLC raised its position in Walgreens Boots Alliance by 0.6% in the fourth quarter. New York Life Investment Management LLC now owns 115,196 shares of the pharmacy operator’s stock valued at $3,008,000 after purchasing an additional 690 shares during the period. EP Wealth Advisors LLC purchased a new position in Walgreens Boots Alliance in the fourth quarter valued at about $297,000. Finally, Corient Private Wealth LLC raised its position in Walgreens Boots Alliance by 38.9% in the fourth quarter. Corient Private Wealth LLC now owns 280,545 shares of the pharmacy operator’s stock valued at $7,325,000 after purchasing an additional 78,523 shares during the period. 58.59% of the stock is owned by institutional investors and hedge funds.

Walgreens Boots Alliance Company Profile

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.